Formerly known as Immusol Inc, iTherX Pharmaceuticals Inc., a biopharmaceutical company, is engaged primarily in the discovery and development of antiviral products for treatment of hepatitis C. - a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. he firm's products include ITX5061, a therapy targeted at inhibiting the entry of the hepatitis C virus (HCV) into liver cells; viral envelope target program to develop small molecule inhibitors of viral entry that targets the HCV envelope proteins; and host cell receptor target program, which engenders small molecule compounds that target a liver cell membrane protein.
